Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  JAK2 inhibitor TG101348
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-6 of 6 for your search:
Start Over
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC12153, 2011-001897-25, U1111-1121-7170, NCT01437787
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARD11936, U1111-1119-2965, NCT01420770
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARD12042, 2011-001847-58, U1111-1121-4203, NCT01420783
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARD12181, 2011-005226-21, U1111-1124-0967, NCT01523171
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INT12497, U1111-1125-8930, NCT01585623
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TES13519, 2012-005642-38, U1111-1115-7323, NCT01836705
Start Over